

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-66 (Cancelled).

67. (Original) A monoclonal antibody which specifically binds to APRIL polypeptide and blocks binding of said APRIL polypeptide to a TACI receptor or a BCMA receptor.

68. (Original) The monoclonal antibody of claim 67 which further blocks binding of said APRIL polypeptide to a TACI receptor and a BCMA receptor.

69 (Amended) The monoclonal antibody of claim 67 wherein said monoclonal antibody ~~comprises~~ is the 3C6.4.2 antibody secreted by the hybridoma deposited with ATCC as accession number PTA-1347.

70. (Amended) A monoclonal antibody [which] that specifically binds to an APRIL polypeptide and binds to the same epitope as the epitope to which the 3C6.4.2 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number PTA-1347 binds.

71 (Original) The hybridoma cell line which produces monoclonal antibody 3C6.4.2 and deposited with ATCC as accession number PTA-1347.

72. (Original) The monoclonal antibody 5E11.1.2 secreted by the hybridoma deposited with ATCC as accession number PTA-1346.

73. (Amended) A monoclonal antibody [which] that specifically binds to an APRIL polypeptide and binds to the same epitope as the epitope to which the 5E11.1.2 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number PTA-1346 binds.

74. (Original) The hybridoma cell line which produces monoclonal antibody 5E11.1.2 and deposited with ATCC as accession number PTA-1346.

75. (Original) The monoclonal antibody 5G8.2.2 secreted by the hybridoma deposited with ATCC as accession number PTA-1345.

76. (Amended) A monoclonal antibody [which] that specifically binds to an APRIL polypeptide and binds to the same epitope as the epitope to which the 5G8.2.2

monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number PTA-1345 binds.

77. (Original) The hybridoma cell line which produces monoclonal antibody 5G8.2.2 and deposited with ATCC as accession number PTA-1345.

78. (Original) The monoclonal antibody 5E8.7.4 secreted by the hybridoma deposited with ATCC as accession number PTA-1344.

79. (Amended) A monoclonal antibody [which] that specifically binds to an APRIL polypeptide and binds to the same epitope as the epitope to which the 5E8.7.4 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number PTA-1344 binds.

80. (Original) The hybridoma cell line which produces monoclonal antibody 5E8.7.4 and deposited with ATCC as accession number PTA-1344.

81. (Original) A chimeric anti-APRIL antibody which specifically binds to APRIL polypeptide and comprises a sequence derived from the 3C6.4.2 antibody secreted by the hybridoma deposited with ATCC as accession number PTA-1347.

82. (Original) A chimeric anti-APRIL antibody which specifically binds to APRIL polypeptide and comprises a sequence derived from the 5E11.1.2 antibody secreted by the hybridoma deposited with ATCC as accession number PTA-1346.

83. (Original) A chimeric anti-APRIL antibody which specifically binds to APRIL polypeptide and comprises a sequence derived from the 5G8.2.2 antibody secreted by the hybridoma deposited with ATCC as accession number PTA-1345.

84. (Original) A chimeric anti-APRIL antibody which specifically binds to APRIL polypeptide and comprises a sequence derived from the 5E8.7.4 antibody secreted by the hybridoma deposited with ATCC as accession number PTA-1344.

85. (Original) A humanized anti-APRIL antibody which specifically binds to APRIL polypeptide and comprises a sequence derived from the 3C6.4.2 antibody secreted by the hybridoma deposited with ATCC as accession number PTA-1347.

86. (Original) A humanized anti-APRIL antibody which specifically binds to APRIL polypeptide and comprises a sequence derived from the 5E11.1.2 antibody secreted by the hybridoma deposited with ATCC as accession number PTA-1346.

87. (Original) A humanized anti-APRIL antibody which specifically binds to APRIL polypeptide and comprises a sequence derived from the 5G8.2.2 antibody secreted by the hybridoma deposited with ATCC as accession number PTA-1345.

88. (Original) A humanized anti-APRIL antibody which specifically binds to APRIL polypeptide and comprises a sequence derived from the 5E8.7.4 antibody secreted by the hybridoma deposited with ATCC as accession number PTA-1344.

89. (Previously presented) A composition comprising the monoclonal antibody according to any one of claims 67-70, 72-73, 75-76 and 78-79 and a carrier.

90. (Previously presented) A composition comprising the chimeric anti-APRIL antibody according to any one of claims 81-84 and a carrier.

91. (Previously presented) A composition comprising the humanized anti-APRIL antibody according to any one of claims 85-88 and a carrier.

92. (Withdrawn) A method of treating an APRIL-related pathological condition in a mammal, wherein the pathological condition is an inflammatory disease, comprising administering to said mammal an effective amount of the monoclonal antibody according to any one of claims 67-70, 72-73 and 78-79.

93. (Withdrawn) A method of treating an APRIL-related pathological condition in a mammal, wherein the pathological condition is an inflammatory disease, comprising administering to said mammal an effective amount of the chimeric anti-APRIL antibody according to any one of claims 81, 82 and 84.

94. (Withdrawn) A method of treating an APRIL-related pathological condition in a mammal, wherein the pathological condition is an inflammatory disease, comprising administering to said mammal an effective amount of the humanized antibody according to any one of claims 85, 86 and 88.

95. (New) An anti-APRIL monoclonal antibody that competitively inhibits the binding of the 3C6.4.2 antibody secreted by the hybridoma deposited with ATCC as accession number PTA-1347 to APRIL.

96. (New) An anti-APRIL monoclonal antibody that competitively inhibits the binding of the 5E11.1.2 antibody secreted by the hybridoma deposited with ATCC as accession number PTA-1346 to APRIL.

97. (New) A method for inhibiting or neutralizing APRIL polypeptide biological activity in mammalian cells, comprising exposing said mammalian cells to an effective amount of the antibody according to any one of claims 67-74, 81-82, 85-86 and 95-96.

Amendments to the Drawings

Please replace Figures 1-20 (29 sheets of drawings) with Figures 1-20 (29 sheets of drawings) submitted herewith. The attached sheets of drawings include changes to improve the size of the margins and quality of the photographs and labels so that they correct to the informalities noted by the Draftsperson on PTO-948 attached to the June 2003 Office Action.